Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2025 | $13.00 | Buy | Canaccord Genuity |
Net sales increased 37% to $31.1 million Gross margin increased 480 basis points to 65.0% Net income of $3.6 million versus breakeven in prior year period Adjusted EBITDA increased by 221% to $5.0 million Raising full year 2025 revenue outlook to 22% to 27% year-over-year growth Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 37% to $31.1 million, with Tru Niagen® sales reaching $22.7 million, growing 22%. Niagen® ingredient sales increased 135% to $7.4 million including food-grade and pharmaceutical-grade. Gross margin
Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity's 45th Annual Growth Conference, taking place from August 12 to 14, 2024, in Boston. Mr. Fried is scheduled to participate in a fireside chat on Tuesday, August 12, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time). To register for the Niagen Bioscience fireside chat webcast, please visit www.wsw.com. Mr. Fried and Mr. Pamir will also hold one-on-one meetings with instituti
Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, August 6, at 4:30 p.m. ET to discuss its financial results for the second quarter 2025, which ended June 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, August 6, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the second quarter 2025 financial results and provide a general business update on Wednesday, Aug
S-8 - Niagen Bioscience, Inc. (0001386570) (Filer)
S-8 - Niagen Bioscience, Inc. (0001386570) (Filer)
8-K - Niagen Bioscience, Inc. (0001386570) (Filer)
Canaccord Genuity initiated coverage of Niagen Bioscience with a rating of Buy and set a new price target of $13.00
4 - Niagen Bioscience, Inc. (0001386570) (Issuer)
4 - Niagen Bioscience, Inc. (0001386570) (Issuer)
4 - Niagen Bioscience, Inc. (0001386570) (Issuer)
Appointment of renowned gerontologist and mitochondrial biology expert underscores Niagen Bioscience's commitment to advancing cutting-edge NAD+ and healthspan research Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board (SAB). Dr. Cohen is an internationally recognized leading expert in healthy aging and mitochondrial biology. He serves as Dean of the University of Southern California (USC) Leonard Davis School of Gerontology and is a Distinguished Professor of Gerontology
Net sales increased 37% to $31.1 million Gross margin increased 480 basis points to 65.0% Net income of $3.6 million versus breakeven in prior year period Adjusted EBITDA increased by 221% to $5.0 million Raising full year 2025 revenue outlook to 22% to 27% year-over-year growth Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 37% to $31.1 million, with Tru Niagen® sales reaching $22.7 million, growing 22%. Niagen® ingredient sales increased 135% to $7.4 million including food-grade and pharmaceutical-grade. Gross margin
Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, August 6, at 4:30 p.m. ET to discuss its financial results for the second quarter 2025, which ended June 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, August 6, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the second quarter 2025 financial results and provide a general business update on Wednesday, Aug
Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook. Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. First Quarter 2025 Financial and Recent Operational Highlights Total net sales were $30.5 million, with $21.5 million from Tru Niagen®, up 38%, and 24%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $8.0 million, up 95% YoY. Delivered strong gross margin of 63.4%,